Compare LVWR & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVWR | AURA |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | 182 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.0M | 377.2M |
| IPO Year | N/A | 2021 |
| Metric | LVWR | AURA |
|---|---|---|
| Price | $1.36 | $6.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | ★ 330.9K | 224.8K |
| Earning Date | 04-30-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $619.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $4.73 |
| 52 Week High | $9.04 | $7.73 |
| Indicator | LVWR | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 62.97 |
| Support Level | $0.93 | $5.83 |
| Resistance Level | $5.14 | $6.67 |
| Average True Range (ATR) | 0.23 | 0.42 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 17.84 | 72.83 |
LiveWire Group Inc is an all-electric vehicle company. It sells electric vehicles and related parts and accessories and apparel in the United States and certain international markets. The company's segment includes Electric Motorcycles and STACYC. Electric Motorcycles segment sells electric motorcycles, related parts and accessories and apparel in the United States and certain international markets; STACYC segment sells electric balance bikes for kids, related parts and accessories and apparel in the United States and certain international markets. LiveWire generates revenue from the sale of electric motorcycles, Parts, accessories and apparel. Majority of revenue is from USA.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.